Kotaro Kodama

Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models

Osamu Tohyama, Junji Matsui, Kotaro Kodama et al. · Journal of Thyroid Research · 2014 · 480 citations · Full text

Medicine, Oncology, Pharmacology +17

Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1‐6 hepatocellular carcinoma model

Takayuki Kimura, Yu Kato, Yoichi Ozawa et al. · Cancer Science · 2018 · 342 citations · Full text

Medicine, Oncology, Pharmacology +17

Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models

Kiyoshi Okamoto, Kotaro Kodama, Kazuma Takase et al. · Cancer Letters · 2013 · 286 citations · Full text

Medicine, Oncology, Pharmacology +17

E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models

Saori Watanabe Miyano, Yuji Yamamoto, Kotaro Kodama et al. · Molecular Cancer Therapeutics · 2016 · 37 citations · Full text

Medicine, Oncology, Pharmacology +16

Novel ATP-Competitive MEK Inhibitor E6201 Is Effective against Vemurafenib-Resistant Melanoma Harboring the MEK1-C121S Mutation in a Preclinical Model

Yusuke Narita, Kiyoshi Okamoto, Megumi Ikemori Kawada et al. · Molecular Cancer Therapeutics · 2014 · 29 citations

Medicine, Oncology, Pharmacology +14